doi: 10.1371/journal.pone.0278685
Upon subcutaneous administration, GHRP-6 violently accelerates gastric emptying and triggers acute, nearly uncontrollable acute hunger phases
The National Institute for Health and Care Excellence (NICE) provides guidance on the use of GLP-1 receptor agonists in guideline NG28, recommending them for type 2 diabetes in specific contexts, such as when other therapies have proven inadequate, particularly in people with higher BMI or cardiovascular risk factors
On Monday morning, Pfizer announced it will be abandoning the development of its GLP-1 drug danuglipron, which was being investigated for chronic weight management
Johnson JA, El Barbary A, Kornguth SE, Brugge JF, Siegel FL
I.Te Lintel HekkertB.SchijlenE.AartsM